[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@DaiichiSankyoUS Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1169299794696818688.png) @DaiichiSankyoUS Daiichi Sankyo US

Daiichi Sankyo US posts on X about $8750t, $4568t, $6417t, breakingnews the most. They currently have XXXXX followers and X posts still getting attention that total XXX engagements in the last XX hours.

### Engagements: XXX [#](/creator/twitter::1169299794696818688/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1169299794696818688/c:line/m:interactions.svg)

- X Week XXX +1,464%
- X Month XXXXX -XX%
- X Months XXXXXXX -XX%
- X Year XXXXXXXXX -XX%

### Mentions: X [#](/creator/twitter::1169299794696818688/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1169299794696818688/c:line/m:posts_active.svg)

- X Week X +100%
- X Month X -XX%
- X Months XX +22%
- X Year XX +763%

### Followers: XXXXX [#](/creator/twitter::1169299794696818688/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1169299794696818688/c:line/m:followers.svg)

- X Week XXXXX no change
- X Month XXXXX +0.16%
- X Months XXXXX +1.40%
- X Year XXXXX +2.70%

### CreatorRank: XXXXXXXXX [#](/creator/twitter::1169299794696818688/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1169299794696818688/c:line/m:influencer_rank.svg)

### Social Influence

**Social topic influence**
[$8750t](/topic/$8750t) #9, [$4568t](/topic/$4568t) #1, [$6417t](/topic/$6417t) #4, [breakingnews](/topic/breakingnews) 50%, [directed](/topic/directed) XX%

**Top accounts mentioned or mentioned by**
[@sabcssanantonio](/creator/undefined) [@gkroub](/creator/undefined)
### Top Social Posts
Top posts by engagements in the last XX hours

"#BREAKINGNEWS: During @SABCSSanAntonio we will present new breast cancer clinical research from more than XX abstracts across our DXd ADC portfolio including updates from five landmark trials. Click for the link to learn more: #SABCS25"  
[X Link](https://x.com/DaiichiSankyoUS/status/1998003857708687422)  2025-12-08T12:16Z 4438 followers, XXX engagements


"#BREAKINGNEWS: We initiated the DESTINY-Ovarian01 phase X trial evaluating our HER2 directed ADC as a combination first-line maintenance therapy in patients with HER2 expressing advanced high-grade epithelial ovarian cancer"  
[X Link](https://x.com/DaiichiSankyoUS/status/1998370568211706251)  2025-12-09T12:34Z 4438 followers, XXX engagements